
    
      OBJECTIVES:

        -  Determine the ability of exisulind to inhibit growth and development of duodenal
           adenomas in patients with familial adenomatous polyposis.

        -  Determine the effect on apoptosis in polyp vs mucosal tissue in these patients when
           treated with this drug.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
      randomized to one of two treatment arms.

        -  Arm I: Patients receive oral exisulind 4 times daily.

        -  Arm II: Patients receive oral placebo 4 times daily. Treatment continues for 1 year.

      PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this
      study.
    
  